Tumor microenvironment-responsive prodrug nanoplatform via co-self-assembly of photothermal agent and IDO inhibitor for enhanced tumor penetration and cancer immunotherapy

Liu, Yijia; Lü, Yan; Zhu, Xianghui; Li, Chao; Yan, Ming; Pan, Jie; Ma, Guilei

doi:10.1016/j.biomaterials.2020.119933

Cited by 84 publications

(55 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This may be attributed to the limited cellular uptake of free ICG molecules. [ 26 ] In sharp contrast, the cytotoxicity of LDH/ICG NPs was more pronounced under the same laser treatment, with the cell viability decreasing from 83.1% to 62.1% when the ICG concentration in LDH/ICG increased from 0.25 to 1 μg mL −1 , due to the facilitated cellular uptake by cells via LDH NPs. [ 27,28 ] Here cancer cell apoptosis can be attributed to the combined photodynamic and photothermal effect (PDT/PTT) based on ICG dual properties upon 808 nm NIR irradiation.…”

Section: Resultsmentioning

confidence: 99%

Creating Structural Defects of Drug‐Free Copper‐Containing Layered Double Hydroxide Nanoparticles to Synergize Photothermal/Photodynamic/Chemodynamic Cancer Therapy

et al. 2020

View full text Add to dashboard Cite

Combination therapy has been extensively studied to achieve a more efficient inhibition of tumor progression. Herein, a nanoplatform based on layered double hydroxide (LDH) nanoparticles (NPs) is specifically constructed for the effective combination breast cancer therapy without the traditional anticancer drug. Cu‐containing LDH NPs loaded with indocyanine green (ICG) are devised with more Cu coordination defects (d‐Cu‐LDH/ICG) to induce photothermal/photodynamic/chemodynamic therapy (PTT/PDT/CDT) using only one laser source. The structurally created defects on the LDH surface and dual‐function ICG molecules in the LDH interlayer significantly enhance photothermal transduction and singlet‐oxygen (1O2) generation at 808 nm laser irradiation. Moreover, d‐Cu‐LDH/ICG NPs generate hydroxyl radicals (·OH) in the presence of H2O2 as Fenton catalysts, which are further enhanced by Cu(II) reduction with glutathione and temperature elevation. Consequently, d‐Cu‐LDH/ICG NPs significantly suppress 4T1 cell proliferation and show effective inhibition of the tumor growth in vivo through only one combined PTT/PDT/CDT under very mild laser irradiation, i.e., at 0.23 W cm−2 for 5 min with very low doses of Cu and ICG (2.5 and 0.5 mg kg−1). Altogether, the defect‐created d‐Cu‐LDH/ICG nanoplatform offers a new and safe treatment option for combination cancer therapy without using any anticancer drugs.

show abstract

Section: Resultsmentioning

confidence: 99%

Creating Structural Defects of Drug‐Free Copper‐Containing Layered Double Hydroxide Nanoparticles to Synergize Photothermal/Photodynamic/Chemodynamic Cancer Therapy

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Despite the favorable results, several studies have shown limited results for complete tumor remission for ICIs with hyperthermia. Thus, triple combination strategies including ICIs with radio-/chemotherapy or TLR agonists have been studied, and they have also achieved favorable results with decreased tumor volume, increased metastatic dissemination, prevention of tumor rechallenge, and improved overall survival (115)(116)(117)(118)(119)(120)(121)(122)(123)(124)(125)(126). A case report also found that hyperthermia and ipilimumab combined with IL-2 achieved complete clinical remission of stage IV triple-negative breast cancer with lung metastasis (127).…”

Section: Preclinical Data Combining Hyperthermia and Icismentioning

confidence: 99%

Hyperthermia Targeting the Tumor Microenvironment Facilitates Immune Checkpoint Inhibitors

Deng

Sun

et al. 2020

Front. Immunol.

View full text Add to dashboard Cite

“…Yang et al designed a supramolecular peptide-based core-shell nanostructure loaded with Indocyanine green (ICG) and IDO inhibitors in response to MMP-2 forming small dual-drug complexes for photothermal immunotherapy. [79] It is worth noting that the supramolecular peptide assemblies have the ability to solve the problem of frequent administration of PD-1 inhibitors, reduce the clearance rate, and maintain long-term release, playing an effect in the combination of photothermal immunotherapy. [80] For clinical PD-1/PD-L1 inhibitor therapy, generally continuous dose (e.g., up to 2 years) is regarded as the standard method of administration, and the current clinical administration is to inject once a day for 1 month to maintain the effective therapeutic concentration in the body.…”

Section: Phototherapy and Immunotherapymentioning

confidence: 99%

Supramolecular Immunotherapy of Cancer Based on the Self‐Assembling Peptide Design

Chang

Yan

2020

Small Structures

View full text Add to dashboard Cite

Supramolecular peptide assemblies with specific motifs have the advantages of high immunogenicity, regulated immune response, and increased multiple functions in improving the performance of cancer immunotherapy, compared with molecular peptide immunotherapy. These peptide-based assemblies with structural and functional versatility can serve as immunotherapeutic agents such as antigens, adjuvants, drug delivery carriers, or immunomodulators. This article reviews the effects of supramolecular peptide assemblies on cancer immunotherapy and highlights the unique role of supramolecular assembly strategies in regulating the immunotherapeutic performance. The mechanism of how the peptide supramolecular self-assembly affects the performance of immunotherapy is critically emphasized. The summary of peptide supramolecular immunotherapy provides a reference for the precise design of adjustable and multifunctional immunotherapeutic agents, and shows that peptide self-assembly has great application prospects in cancer immunotherapy.

show abstract

Tumor microenvironment-responsive prodrug nanoplatform via co-self-assembly of photothermal agent and IDO inhibitor for enhanced tumor penetration and cancer immunotherapy

Cited by 84 publications

References 43 publications

Creating Structural Defects of Drug‐Free Copper‐Containing Layered Double Hydroxide Nanoparticles to Synergize Photothermal/Photodynamic/Chemodynamic Cancer Therapy

Creating Structural Defects of Drug‐Free Copper‐Containing Layered Double Hydroxide Nanoparticles to Synergize Photothermal/Photodynamic/Chemodynamic Cancer Therapy

Hyperthermia Targeting the Tumor Microenvironment Facilitates Immune Checkpoint Inhibitors

Supramolecular Immunotherapy of Cancer Based on the Self‐Assembling Peptide Design

Contact Info

Product

Resources

About